Brazil's Bio-Manguinhos Invests More than $600 Million in Biosimilar New Final Processing Center
Brazil's Bio-Manguinhos Invests More than $600 Million in Biosimilar New Final Processing Center
Attachment: fill
Industrial Info is tracking a grassroot biosimilar complex, named New Final Processing Center, that Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos is constructing in Santa Cruz, Rio de Janeiro, Brazil. The facility will include all needed production areas, from the raw material storage to fill and finish, packaging and final product storage, along with laboratories, utilities and administrative areas, to conform the Health Biotechnology Industrial Complex (CIBS).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Brazil Sees US$5.5 Billion in Grassroot Pharmaceutical-Biotech
- Brazil's Bio-Manguinhos Institute Constructs Grassroot Site in Rio de Janei...
- Brazil's Bio-Manguinhos Institute Still in Bidding Process for Oxford's COV...
- Brazil Plans to Produce Oxford's COVID-19 Vaccine, an Industrial Info Marke...
- México registra inversiones por 2 mil millones de dólares en el sector farm...